AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|
14.9 C
New York
Tuesday, October 27, 2026

Tag: pharmaceutical

newsFORsourcecompanycontentinformation1releasesmarket

Helus Pharma™ Announces US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership

ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu...

Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership

ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu...

McKesson Selects Moore, Oklahoma for a State-of-the-Art Regional Distribution Center Positions Cleveland County as a National Healthcare Supply Chain Hub

MOORE, Okla., June 23, 2026 /PRNewswire/ -- Today, the Oklahoma Department of Commerce and the Cleveland County Economic Development Coalition announced that announced that...

PHREESIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities...

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

Valiant Energy Management Acquires VanDeMark Chemical

Acquisition Preserves Domestic Specialty Chemical Manufacturing Platform and Positions Business for Future GrowthLOCKPORT, N.Y., June 22, 2026 /PRNewswire/ -- Valiant Energy Management, LLC ("Valiant")...

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

Sodexo appoints Agnès Park as Group Chief Human Resources Officer    

Issy-les-Moulineaux, June 22, 2026

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi appoints Paulo Fontoura as Global Head of R&D

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and...

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a...

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers